HDAC3 and central nervous system disorder: RGFP966, a highly selective HDAC3 inhibitor, has demonstrated neuroinhibitory and neuroprotective impacts in several central nervous system diseases, encompassing neurodegenerative diseases [29], cerebral ischemia [30] and spinal cord injury [31].